Amend 003 - Hepatitis A and B Adult and Pediatric - GlaxoSmithKline Inc.
Contract number E60PH-22HEAB/001/PH
Solicitation number E60PH-22HEAB/A
Contract award date
Expiry date
Amendment date
Amendment value CAD 277,398.00
Contract number E60PH-22HEAB/001/PH
Solicitation number E60PH-22HEAB/A
Contract award date
Expiry date
Amendment date
Amendment value CAD 277,398.00
The contract will be for a period of 24 month(s), from 2022/03/03 to 2024/03/31.
This is the total value of this contract, which includes the initial contract value and the sum of all amendments.
CAD 13,587,803.61
A contracting officer can use limited tendering for specific reasons outlined in the applicable trade agreements. The reason for this contract is described below: